



Teva's
Position on
Antimicrobial
Resistance
(AMR)

teva

Collaborating to achieve global solutions

Antimicrobial resistance (AMR) has been increasing dramatically around the globe. Combating the growth of bacterial resistance to antibiotics is a top priority for global public health, with concerns that antibiotics are losing effectiveness faster than they are being replaced by new, innovative drugs, and alternative non-antibiotic approaches to treating and preventing infections. Currently it is estimated that more than 700,000 people die every year as a result of antibiotic resistance, and these numbers are expected to rise significantly over the coming decades if this disturbing trend is not curbed.

As a leading global manufacturer of medicines and health solutions, Teva embraces a global collaborative focus on developing solutions to the issue of antimicrobial resistance (AMR), and commits to working with industry peers and global health organizations to identify solutions that will help protect people and provide new ways to reduce AMR.

Following discussions at the World Economic forum in Davos, Switzerland in 2016, the global pharmaceutical industry and health organizations came together to commit to collective action. Teva was proud to be among members of the life sciences industry who joined the resulting [AMR Industry Alliance](#), committed to finding solutions to this issue together.

Committed to finding solutions

As a partner to the industry, health associations and regulators in finding solutions to AMR, we commit to:

- Antibiotics only being used in patients who need them; continued education for clinical professionals on appropriate use; and a WHO Global Action Plan focused on improved stewardship.
- Encourage infection control via improved hygiene, vaccination, and preventive treatments to help reduce the number of infections needing antibiotic treatment.
- Support measures to reduce environmental impact from antibiotics, along with a 'one health' approach towards prudent and responsible use, including a global reduction of unnecessary antibiotic use in livestock.
- As acknowledged, the value assigned to antibiotics and diagnostics often does not reflect the investment required for their creation or the benefits they bring to society, and we stand ready to work with payers and policymakers on new valuation mechanisms and commercial models that specifically address the unique challenges of this market.

- Support new ways of working such as open collaborations between industry and public researchers to overcome the scientific challenges of creating new antibiotics and diagnostics. Collaborative public-private projects already demonstrate what we can achieve together, but more can be done.
- Support mechanisms to ensure affordable access to new and existing antibiotics to the patients who need them, in all parts of the world and at all levels of income, as part of the WHO Global Action Plan's proposal for a comprehensive program of sanitation, hygiene, vaccination, infection control, education, and stewardship.
- Recognize the success of programs to improve global access to drugs in HIV, TB, and malaria and call for a similar collaborative effort to address issues of access to antibiotics

Through these actions, we aim to be active partners in the fight against AMR and to enable millions of people live healthier, better days.

[Learn more about AMR on the International Federation of Pharmaceutical Manufacturers and Associations \(IFPMA\) website](#)

[Learn more about the AMR Industry Alliance](#)